Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has signed an exclusive three-year agreement with Belgian-US molecular diagnostic company MDxHealth SA (Euronext: MDXH) to commercialize two of the company's cancer tests in Israel. The agreement covers ConfirmMDx for prostate cancer and PredictMDx for Glioblastoma, a brain cancer.
ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies. The PredictMDx test is used to identify glioma patients who have methylation of the Glioblastoma (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.
Teva will be the exclusive distributor of both tests in Israel. Samples will be sent to MDxHealth's CLIA-registered laboratory in Irvine, California, for analysis. Teva will reimburse MDxHealth for all the testing services.
"This partnership with Teva means that these important tests will now become available to cancer patients in Israel, our second market after the US," said MDxHealth CEO Dr. Jan Groen. "We are delighted that Teva has agreed to invest its significant commercialization resources into our unique cancer products, expanding access to a new and diverse patient population."
Published by Globes [online], Israel business news - www.globes-online.com - on January 23, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014